Stocks · News reference
Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
Medpace says second-quarter earnings and revenue beat estimates, backed by stronger bookings, backlog growth and higher 2026 guidance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665
Mizuho analyst Ann Hynes maintains Medpace Holdings (NASDAQ:MEDP) with a Outperform and raises the price target from $586 to $665.
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600
BMO Capital analyst Sean Dodge maintains Medpace Holdings (NASDAQ:MEDP) with a Market Perform and raises the price target from $400 to $600.